newsfilter
← Latest News
Business Wire·

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today